121 related articles for article (PubMed ID: 12410519)
1. Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium.
Chou TM; Woodburn KW; Cheong WF; Lacy SA; Sudhir K; Adelman DC; Wahr D
Catheter Cardiovasc Interv; 2002 Nov; 57(3):387-94. PubMed ID: 12410519
[TBL] [Abstract][Full Text] [Related]
2. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results.
Kereiakes DJ; Szyniszewski AM; Wahr D; Herrmann HC; Simon DI; Rogers C; Kramer P; Shear W; Yeung AC; Shunk KA; Chou TM; Popma J; Fitzgerald P; Carroll TE; Forer D; Adelman DC
Circulation; 2003 Sep; 108(11):1310-5. PubMed ID: 12939212
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.
Ross HM; Smelstoys JA; Davis GJ; Kapatkin AS; Del Piero F; Reineke E; Wang H; Zhu TC; Busch TM; Yodh AG; Hahn SM
J Surg Res; 2006 Oct; 135(2):323-30. PubMed ID: 16650871
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy with motexafin lutetium induces redox-sensitive apoptosis of vascular cells.
Chen Z; Woodburn KW; Shi C; Adelman DC; Rogers C; Simon DI
Arterioscler Thromb Vasc Biol; 2001 May; 21(5):759-64. PubMed ID: 11348871
[TBL] [Abstract][Full Text] [Related]
5. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
Verigos K; Stripp DC; Mick R; Zhu TC; Whittington R; Smith D; Dimofte A; Finlay J; Busch TM; Tochner ZA; Malkowicz S; Glatstein E; Hahn SM
J Environ Pathol Toxicol Oncol; 2006; 25(1-2):373-87. PubMed ID: 16566729
[TBL] [Abstract][Full Text] [Related]
6. Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin).
Rockson SG; Kramer P; Razavi M; Szuba A; Filardo S; Fitzgerald P; Cooke JP; Yousuf S; DeVault AR; Renschler MF; Adelman DC
Circulation; 2000 Nov; 102(19):2322-4. PubMed ID: 11067782
[TBL] [Abstract][Full Text] [Related]
7. Reduction of vein graft disease using photodynamic therapy with motexafin lutetium in a rodent isograft model.
Yamaguchi A; Woodburn KW; Hayase M; Robbins RC
Circulation; 2000 Nov; 102(19 Suppl 3):III275-80. PubMed ID: 11082401
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of in-stent restenosis in rabbit iliac arteries with photodynamic therapy.
Pai M; Jamal W; Mosse A; Bishop C; Bown S; McEwan J
Eur J Vasc Endovasc Surg; 2005 Dec; 30(6):573-81. PubMed ID: 16125418
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy with motexafin lutetium (Lu-Tex) reduces experimental graft coronary artery disease.
Yamaguchi A; Woodburn KW; Hayase M; Hoyt G; Robbins RC
Transplantation; 2001 Jun; 71(11):1526-32. PubMed ID: 11435960
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy in the canine prostate using motexafin lutetium.
Hsi RA; Kapatkin A; Strandberg J; Zhu T; Vulcan T; Solonenko M; Rodriguez C; Chang J; Saunders M; Mason N; Hahn S
Clin Cancer Res; 2001 Mar; 7(3):651-60. PubMed ID: 11297261
[TBL] [Abstract][Full Text] [Related]
11. Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light.
Yu G; Durduran T; Zhou C; Zhu TC; Finlay JC; Busch TM; Malkowicz SB; Hahn SM; Yodh AG
Photochem Photobiol; 2006; 82(5):1279-84. PubMed ID: 16696593
[TBL] [Abstract][Full Text] [Related]
12. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer.
Dimofte A; Zhu TC; Hahn SM; Lustig RA
Lasers Surg Med; 2002; 31(5):305-12. PubMed ID: 12430147
[TBL] [Abstract][Full Text] [Related]
13. Phototherapy of cancer and atheromatous plaque with texaphyrins.
Woodburn KW; Fan Q; Kessel D; Wright M; Mody TD; Hemmi G; Magda D; Sessler JL; Dow WC; Miller RA; Young SW
J Clin Laser Med Surg; 1996 Oct; 14(5):343-8. PubMed ID: 9612202
[TBL] [Abstract][Full Text] [Related]
14. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.
Du KL; Mick R; Busch TM; Zhu TC; Finlay JC; Yu G; Yodh AG; Malkowicz SB; Smith D; Whittington R; Stripp D; Hahn SM
Lasers Surg Med; 2006 Jun; 38(5):427-34. PubMed ID: 16788929
[TBL] [Abstract][Full Text] [Related]
15. Motexafin lutetium (Pharmacyclics).
Yeung PF
IDrugs; 2001 Mar; 4(3):351-9. PubMed ID: 16025394
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model.
Griffin GM; Zhu T; Solonenko M; Del Piero F; Kapakin A; Busch TM; Yodh A; Polin G; Bauer T; Fraker D; Hahn SM
Clin Cancer Res; 2001 Feb; 7(2):374-81. PubMed ID: 11234893
[TBL] [Abstract][Full Text] [Related]
17. Photoangioplasty: An emerging clinical cardiovascular role for photodynamic therapy.
Rockson SG; Lorenz DP; Cheong WF; Woodburn KW
Circulation; 2000 Aug; 102(5):591-6. PubMed ID: 10920074
[TBL] [Abstract][Full Text] [Related]
18. PhotoPoint photodynamic therapy promotes stabilization of atherosclerotic plaques and inhibits plaque progression.
Waksman R; McEwan PE; Moore TI; Pakala R; Kolodgie FD; Hellinga DG; Seabron RC; Rychnovsky SJ; Vasek J; Scott RW; Virmani R
J Am Coll Cardiol; 2008 Sep; 52(12):1024-32. PubMed ID: 18786486
[TBL] [Abstract][Full Text] [Related]
19. Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate.
Busch TM; Wang HW; Wileyto EP; Yu G; Bunte RM
Radiat Res; 2010 Sep; 174(3):331-40. PubMed ID: 20726728
[TBL] [Abstract][Full Text] [Related]
20. In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates.
Solonenko M; Cheung R; Busch TM; Kachur A; Griffin GM; Vulcan T; Zhu TC; Wang HW; Hahn SM; Yodh AG
Phys Med Biol; 2002 Mar; 47(6):857-73. PubMed ID: 11936174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
